Portal de Periódicos da CAPES

Multiple myeloma — a curable disease?

1992; Wiley; Volume: 231; Issue: 5 Linguagem: Romeno

10.1111/j.1365-2796.1992.tb00959.x

1365-2796

Gösta Gahrton,

Hematological disorders and diagnostics

Journal of Internal MedicineVolume 231, Issue 5 p. 449-452 Free Access Multiple myeloma — a curable disease? Gösta Gahrton MD, Gösta Gahrton MD Department of Medicine Huddinge Hospital Karolinska Institute S-10401 Stockholm SwedenSearch for more papers by this author Gösta Gahrton MD, Gösta Gahrton MD Department of Medicine Huddinge Hospital Karolinska Institute S-10401 Stockholm SwedenSearch for more papers by this author First published: May 1992 https://doi.org/10.1111/j.1365-2796.1992.tb00959.xCitations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Kyle RA. History of multiple myeloma. In: PH Wiernik, GP Canellos, RA Kyle, CA Schiffer, eds. Neoplastic Diseases of the Blood, 2nd edn. Edinburgh: Churchill Livingstone, 1991; 325–32. 2 Bergsagel D, Sprague CC, Austin C, Griffith KM. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-phenylalanine mustard (NSC-8806). Cancer Chemother Rep 1962; 21: 87. 3 Alexanian R, Haut H, Khan A et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. J Am Med Assoc 1969; 208: 1680–5. 4 McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet 1983; 1: 822–4. 5 Selby P, McElwain TJ, Nanci AC et al. Multiple myeloma treated with high dose intravenous melaphalan. Br J Haematol 1987; 66: 55–62. 6 Barlogie B, Alexanian R, Dicke K et al. High dose chemo-radiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869–72. 7 Jagannath S, Barlogie B, Dicke K et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 1990; 76: 1860–6. 8 Anderson KC, Barut A, Ritz J et al. Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood 1991; 77: 712–20. 9 Gobbi M, Cavo M, Tazzari PL et al. Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma. Eur J Haematol 1989; 43 (Suppl. 521): 176–81. 10 Dinota A, Tazzari PL, Abbondanza A, Battelli MG, Gobbi M, Stirpe F. Bone marrow purging by a xanthine oxidase-antibody conjugate. Bone Marrow Transplant 1990; 6: 31–6. 11 Barlogie B, Jagannath S, Dixon DO et al. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 1990; 76: 677–80. 12 Gahrton G, Ringdén O, Lönnqvist B, Lindquist R, Ljungman P. Bone marrow transplantation in three patients with multiple myeloma. Acta Med Scand 1986; 219: 523–7. 13 Tura S, Cavo M, Baccarani M, Ricci P, Gobbi M. Bone marrow transplantation in multiple myeloma. Scand J Haematol 1986; 36: 186–9. 14 Gahrton G, Tura S, Flesch M et al. Bone marrow transplantation in multiple myeloma: Report from the European Cooperative Group for Bone Marrow Transplantation. Blood 1987; 69: 1262–4. 15 Gahrton G, Tura S, Flesch M et al. Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the EBMT registry. Hematol Oncol 1988; 6: 181–6. 16 Gahrton G, Tura S, Ljungman P et al. Allogeneic marrow transplantation in multiple myeloma using HLA-matched sibling donors. N Engl J Med 1991; 325: 1267–73. 17 Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155–63. 18 Mellstedt H, Ahre A, Björkholm M, Holm G, Johansson B, Strander H. Interferon therapy in myleomatosis. Lancet 1979; 1: 245–7. 19 Mellstedt H, Österborg A, Björkholm M et al. Induction treatment with α-interferon in multiple myeloma — an interim report from MGCS. Eur J Haematol 1989; 43: 124–8. 20 Mandelli F, Avvisari G, Amadori S et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 32: 1430–4. 21 Hows JM, Bradley BA. The use of unrelated marrow donors for transplantation. Br J Haematol 1990; 76: 1–6. 22 van Rood JJ. For the Editorial Board of the Bone Marrow Donors Worldwide (BMDW). Bone Marrow Donors World Wide. 6th edn, June 1991. 23 Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation of patients with multiple myeloma - Report from the EBMT registry. In: A Pileri, M Boccadoro, eds. Third International Workshop on Myeloma; Advances in Biology and Therapy. Torino, Italy, 1991; 121 (abstract). 24 Mackinnon S, Hows JM, Goldman JM et al. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. Exp Hematol 1990; 18: 421–5. Citing Literature Volume231, Issue5May 1992Pages 449-452 ReferencesRelatedInformation